Macrogenics reported $367M in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Amgen AMGN:US $ 19099M 2200M
AstraZeneca AZN:LN 27.27B 8.54B
Biogen BIIB:US $ 7183.7M 464.2M
Bristol Myers Squibb BMY:US $ 29161M 2050M
Cerulean Pharma CERU:US $ 14.06M 4.46M
Daiichi Sankyo 4568:JP Y 1233697M 34723M
Dicerna Pharmaceuticals DRNA:US $ 616.49M 21.99M
Eli Lilly And LLY:US $ 17295.5M 691M
Epizyme EPZM:US $ 272.49M 67.93M
Genmab GEN:DC 20.3B 367M
Geron GERN:US $ 201.76M 13.5M
Gilead Sciences GILD:US $ 14498M 1220M
Immunogen IMGN:US $ 274.4M 45.18M
Karyopharm Therapeutics KPTI:US $ 273.5M 17.99M
Macrogenics MGNX:US $ 367M 7.72M
Mirati Therapeutics MRTX:US $ 1278.09M 25.42M
Puma Biotechnology PBYI:US $ 167.75M 3.99M
Regeneron Pharmaceuticals REGN:US $ 13337.6M 3282.5M
Seattle Genetics SGEN:US $ 3098.51M 5.18M
Xencor XNCR:US $ 480.97M 110.2M